Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders.
Phase of Trial: Phase I/II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Rivogenlecleucel (Primary)
- Indications Haemoglobinopathies; Immunodeficiency disorders; Leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Bellicum Pharmaceuticals
- 01 Feb 2018 Status changed to recruiting.
- 10 Jan 2018 New trial record